Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India consults on national policy to promote, protect local medical device industry

This article was originally published in SRA

Executive Summary

The Indian government is inviting feedback on its first ever national-level policy on medical devices that aims to support the domestic medtech industry through a variety of measures, such as by creating a separate National Medical Device Authority (NMDA), changing the tax/duty structure to promote and protect local device companies, and creating a separate regulator for medtech pricing issues1.

You may also be interested in...



India Can Do More To Align New Medtech Regulations With Global Norms, Says Industry

India will finally get a device-specific regulatory framework when new rules formed by the government come into force next year. While the medtech industry has welcomed this long-awaited development, it hopes that its outstanding concerns will be addressed before the rules come into play.

Saudi FDA Finalizes Approach To Commercial Info In Public Assessment Reports

Saudi Arabia has explained what information on a drug’s review will be made public following a marketing authorization decision. 

EU Finalizes Option To Omit Expiry Date On Inner Labeling Of Investigational Drugs

Revised labeling requirements for unauthorized investigational and auxiliary medicinal products under the EU Clinical Trial Regulation have been published in the Official Journal.

Latest News
See All
UsernamePublicRestriction

Register

MT040530

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel